Analysts Anticipate 10% Upside For ESGU
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 09 2025
0mins
Source: NASDAQ.COM
ETF Analyst Target Prices: The iShares ESG Aware MSCI USA ETF (ESGU) has an implied analyst target price of $144.68, indicating a potential upside of 10.29% from its current trading price of $131.18. Notable underlying holdings with significant upside include ONEOK Inc, CVS Health Corporation, and Targa Resources Corp.
Investor Considerations: Analysts' target prices may reflect optimism about future stock performance, but investors should conduct further research to determine if these targets are justified or overly optimistic based on recent developments in the companies and their industries.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVS
Wall Street analysts forecast CVS stock price to fall
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 104.810
Low
91.00
Averages
96.71
High
105.00
Current: 104.810
Low
91.00
Averages
96.71
High
105.00
About CVS
CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. The Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and, through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vanguard Research Bullish on U.S. Economic Outlook
- GDP Growth Forecast: Vanguard's research projects a 3% growth in U.S. GDP by 2027, which is likely to positively impact U.S. stock markets, especially with core inflation expected to drop to 2.7%, potentially boosting bond prices.
- Value Stock Investment Opportunity: The research highlights that U.S. value stocks could be a good investment choice, as these companies are positioned to benefit from AI productivity gains without incurring upfront costs for AI data centers and capital expenditures, thereby enhancing investor return potential.
- Vanguard Value Factor ETF Performance: The Vanguard U.S. Value Factor ETF (VFVA) has seen a 28.1% increase over the past year and a 12.9% gain in the first half of 2023, underscoring its significance in a diversified portfolio, particularly with holdings across financials, consumer discretionary, and healthcare sectors.
- Bond Market Outlook: The Vanguard Total Bond Market ETF (BND) has delivered an average annual return of 3.1% since its inception in 2007, despite only 0.1% over the past five years; however, if inflation and interest rates decline as projected, future bond investments could yield better returns.
See More
Vanguard Research Bullish on Value Stocks and Bonds
- Value Stock Investment Opportunity: The Vanguard U.S. Value Factor ETF has outperformed the S&P 500 index with a 28.1% annual return over the past year, and its P/E ratio of 11 indicates a significant discount compared to the S&P 500's 25, suggesting that value stocks could be a good investment choice in the coming years.
- Bond Market Outlook: Despite the Vanguard Total Bond Market ETF's average annual return of only 0.1% over the past five years, it has delivered an average annual return of 3.1% since its inception in 2007, indicating potential for long-term investment, especially as inflation and interest rates may decline.
- Diversified Portfolio: The Vanguard U.S. Value Factor ETF holds a portfolio of 649 stocks across large-cap, mid-cap, and small-cap categories, with top sector holdings including financials (23.5%) and consumer discretionary (18.5%), ensuring broad diversification and reducing sector-specific risks.
- Low Cost Advantage: The Vanguard Total Bond Market ETF features an ultra-low expense ratio of 0.03%, making it a cost-effective option in the bond ETF space, and its diversified portfolio of 11,455 bonds provides a solid yield potential, making it suitable for a long-term investor's diversified strategy.
See More
Elevance Health Sues CMS Over Medicare Advantage Ratings
- Lawsuit Background: Elevance Health has filed a lawsuit against the Centers for Medicare & Medicaid Services (CMS), alleging unfair adjustments to a competitor's Medicare Advantage Star Ratings after finalization, claiming this created an uneven competitive landscape.
- Financial Impact: Elevance estimates that the disputed CMS decision cost it approximately $115 million in Medicare Advantage quality bonus payments, directly affecting its financial performance and market competitiveness.
- Industry Implications: Should the court side with Elevance, CMS may be compelled to revisit its ratings process, potentially impacting payments and competitive positioning across the industry, which could lead to similar adjustments for other insurers.
- Future Outlook: Elevance argues that all insurers should be treated under the same rules post-rating release rather than allowing company-specific adjustments, and the outcome of this lawsuit could significantly influence the future earnings growth of insurers heavily reliant on Medicare Advantage.
See More
Medicare Begins Coverage for Obesity Drugs
- Policy Shift: Medicare's new temporary program covers obesity drugs for the first time, potentially enabling millions of older Americans to afford GLP-1 medications from Novo Nordisk and Eli Lilly, significantly improving their health outcomes and quality of life.
- Patient Education Initiatives: Walmart and CVS Health have launched a nationwide effort at nearly 5,000 locations to provide educational materials and pharmacy support, addressing the fact that 82% of older Americans were unaware of the new coverage, thereby enhancing patient engagement and understanding.
- Digital Tool Innovations: Walmart's Everyday Health Signals program helps seniors review their grocery purchases and recommend healthier alternatives, aiming to empower patients in managing their health and ensuring effective medication use.
- Pharmacy Professional Support: Pharmacists from Walmart and CVS will offer one-on-one consultations to assist patients in understanding treatment steps and managing side effects, particularly in medically underserved areas, thereby greatly enhancing patient care accessibility and experience.
See More
Medicare's New Coverage for Obesity Drugs
- New Medicare Policy: Starting Wednesday, eligible seniors can access GLP-1 obesity drugs for a $50 monthly copay, a move expected to unlock access for millions of Medicare beneficiaries who previously could not afford such treatments, significantly improving their health outcomes.
- Potential Patient Pool: Estimates from Novo Nordisk and Eli Lilly suggest that around 15 to 20 million older adults in Medicare qualify for weight loss drugs, presenting a substantial market opportunity for both companies that could drive significant sales growth in the coming years.
- Implementation Challenges: While the new policy enhances drug accessibility, physicians must submit cumbersome prior authorization requests to certify patient eligibility, which may lead to delays in patients receiving their medications, potentially impacting overall treatment effectiveness.
- Future Uncertainty: The policy is set to expire at the end of 2027, raising concerns about whether patients will be able to continue their treatments long-term; experts are advocating for legislation to ensure ongoing coverage for obesity drugs to prevent patients from losing access after successful treatment.
See More
CVS Health Launches GLP-1 Medication Program to Boost Revenue
- Significant Market Potential: CVS Health has launched a GLP-1 medication program aimed at facilitating easier access to weight-loss drugs through virtual consultations and prescriptions, which is expected to significantly boost revenue in its retail pharmacy division.
- Affordable Pricing: The program allows insured patients to pay only $25 per month, eligible Medicare patients $50, and uninsured patients starting at $149, which is likely to attract more patients to CVS's services and enhance customer loyalty.
- Financial Recovery: CVS Health has performed well over the past 18 months, with Q1 revenue growing 6% year-over-year to $100.4 billion and adjusted EPS rising 14% to $2.57, indicating significant progress in cost control.
- Long-term Investment Value: With a dividend yield of 2.5%, well above the S&P 500's 1.1%, and a 56.5% increase in dividends over the past decade, CVS Health presents an attractive option for long-term investors, especially amid ongoing expansion in the healthcare sector.
See More
Vanguard Research Bullish on U.S. Economic Outlook
- GDP Growth Forecast: Vanguard's research projects a 3% growth in U.S. GDP by 2027, which is likely to positively impact U.S. stock markets, especially with core inflation expected to drop to 2.7%, potentially boosting bond prices.
- Value Stock Investment Opportunity: The research highlights that U.S. value stocks could be a good investment choice, as these companies are positioned to benefit from AI productivity gains without incurring upfront costs for AI data centers and capital expenditures, thereby enhancing investor return potential.
- Vanguard Value Factor ETF Performance: The Vanguard U.S. Value Factor ETF (VFVA) has seen a 28.1% increase over the past year and a 12.9% gain in the first half of 2023, underscoring its significance in a diversified portfolio, particularly with holdings across financials, consumer discretionary, and healthcare sectors.
- Bond Market Outlook: The Vanguard Total Bond Market ETF (BND) has delivered an average annual return of 3.1% since its inception in 2007, despite only 0.1% over the past five years; however, if inflation and interest rates decline as projected, future bond investments could yield better returns.
See More
Vanguard Research Bullish on Value Stocks and Bonds
- Value Stock Investment Opportunity: The Vanguard U.S. Value Factor ETF has outperformed the S&P 500 index with a 28.1% annual return over the past year, and its P/E ratio of 11 indicates a significant discount compared to the S&P 500's 25, suggesting that value stocks could be a good investment choice in the coming years.
- Bond Market Outlook: Despite the Vanguard Total Bond Market ETF's average annual return of only 0.1% over the past five years, it has delivered an average annual return of 3.1% since its inception in 2007, indicating potential for long-term investment, especially as inflation and interest rates may decline.
- Diversified Portfolio: The Vanguard U.S. Value Factor ETF holds a portfolio of 649 stocks across large-cap, mid-cap, and small-cap categories, with top sector holdings including financials (23.5%) and consumer discretionary (18.5%), ensuring broad diversification and reducing sector-specific risks.
- Low Cost Advantage: The Vanguard Total Bond Market ETF features an ultra-low expense ratio of 0.03%, making it a cost-effective option in the bond ETF space, and its diversified portfolio of 11,455 bonds provides a solid yield potential, making it suitable for a long-term investor's diversified strategy.
See More
Elevance Health Sues CMS Over Medicare Advantage Ratings
- Lawsuit Background: Elevance Health has filed a lawsuit against the Centers for Medicare & Medicaid Services (CMS), alleging unfair adjustments to a competitor's Medicare Advantage Star Ratings after finalization, claiming this created an uneven competitive landscape.
- Financial Impact: Elevance estimates that the disputed CMS decision cost it approximately $115 million in Medicare Advantage quality bonus payments, directly affecting its financial performance and market competitiveness.
- Industry Implications: Should the court side with Elevance, CMS may be compelled to revisit its ratings process, potentially impacting payments and competitive positioning across the industry, which could lead to similar adjustments for other insurers.
- Future Outlook: Elevance argues that all insurers should be treated under the same rules post-rating release rather than allowing company-specific adjustments, and the outcome of this lawsuit could significantly influence the future earnings growth of insurers heavily reliant on Medicare Advantage.
See More
Medicare Begins Coverage for Obesity Drugs
- Policy Shift: Medicare's new temporary program covers obesity drugs for the first time, potentially enabling millions of older Americans to afford GLP-1 medications from Novo Nordisk and Eli Lilly, significantly improving their health outcomes and quality of life.
- Patient Education Initiatives: Walmart and CVS Health have launched a nationwide effort at nearly 5,000 locations to provide educational materials and pharmacy support, addressing the fact that 82% of older Americans were unaware of the new coverage, thereby enhancing patient engagement and understanding.
- Digital Tool Innovations: Walmart's Everyday Health Signals program helps seniors review their grocery purchases and recommend healthier alternatives, aiming to empower patients in managing their health and ensuring effective medication use.
- Pharmacy Professional Support: Pharmacists from Walmart and CVS will offer one-on-one consultations to assist patients in understanding treatment steps and managing side effects, particularly in medically underserved areas, thereby greatly enhancing patient care accessibility and experience.
See More
Medicare's New Coverage for Obesity Drugs
- New Medicare Policy: Starting Wednesday, eligible seniors can access GLP-1 obesity drugs for a $50 monthly copay, a move expected to unlock access for millions of Medicare beneficiaries who previously could not afford such treatments, significantly improving their health outcomes.
- Potential Patient Pool: Estimates from Novo Nordisk and Eli Lilly suggest that around 15 to 20 million older adults in Medicare qualify for weight loss drugs, presenting a substantial market opportunity for both companies that could drive significant sales growth in the coming years.
- Implementation Challenges: While the new policy enhances drug accessibility, physicians must submit cumbersome prior authorization requests to certify patient eligibility, which may lead to delays in patients receiving their medications, potentially impacting overall treatment effectiveness.
- Future Uncertainty: The policy is set to expire at the end of 2027, raising concerns about whether patients will be able to continue their treatments long-term; experts are advocating for legislation to ensure ongoing coverage for obesity drugs to prevent patients from losing access after successful treatment.
See More
CVS Health Launches GLP-1 Medication Program to Boost Revenue
- Significant Market Potential: CVS Health has launched a GLP-1 medication program aimed at facilitating easier access to weight-loss drugs through virtual consultations and prescriptions, which is expected to significantly boost revenue in its retail pharmacy division.
- Affordable Pricing: The program allows insured patients to pay only $25 per month, eligible Medicare patients $50, and uninsured patients starting at $149, which is likely to attract more patients to CVS's services and enhance customer loyalty.
- Financial Recovery: CVS Health has performed well over the past 18 months, with Q1 revenue growing 6% year-over-year to $100.4 billion and adjusted EPS rising 14% to $2.57, indicating significant progress in cost control.
- Long-term Investment Value: With a dividend yield of 2.5%, well above the S&P 500's 1.1%, and a 56.5% increase in dividends over the past decade, CVS Health presents an attractive option for long-term investors, especially amid ongoing expansion in the healthcare sector.
See More
